Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Investigating the role of MBD1 isoforms in myelodysplastic syndrome

EF 2019-20

Résumé
"1 in 1000 Canadians over 65 will develop myelodysplastic syndrome (MDS), which causes deficiencies in mature blood cells due to malignant hematopoietic stem cells (HSCs) and may progress to secondary acute myeloid leukemia. The only cure for MDS are bone marrow (BM) transplants which are dangerous for elderly patients, indicating a need for new therapeutics. Splicing factors are mutated in 60% of cases, suggesting that RNA splicing may be a key pathogenic pathway. By analyzing RNA sequencing data from healthy and MDS BM, we identified MBD1, a DNA binding protein that represses gene expression, as a globally mis-spliced transcript in MDS and a candidate therapeutic target. We identified exon inclusion events that add new repressive capabilities, potentially representing therapeutically relevant gain-of-function events. As most causal mis-spliced transcripts in MDS are loss-of-function isoforms, our identification of MBD1 mis-splicing may highlight a novel mechanism through which alternative splicing can contribute to MDS. In this project, my two objectives are to determine whether increased inclusion of exon 10 or 12 promotes MDS pathology, and the associated mechanism. For my first objective, I will use lentivirally encoded dCasRx to perform exon knockdown and overexpression in the MDSL cell line and primary MDS samples to run clonal competitive assays to define whether exon 10 or 12 promote MDS growth. For my second objective, I will use integrative CHIP-seq and RNA-seq on primary MDS samples and healthy human HSCs to determine altered promoter binding and gene repression due to MBD1 mis-splicing. By studying MBD1 mis-splicing in MDS, I will uncover a new and tractable therapeutic target for MDS while uncovering new ways through which splicing can contribute to MDS."
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
428865
Name
Joshi Pratik
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the role of MBD1 isoforms in myelodysplastic syndrome
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Chromatin Structure; Dna Binding Proteins; Epigentic Regulation; Hematopoietic Stem Cells; Leukemia; Myelodysplastic Syndrome; Rna Binding Proteins; Rna Splicing; Self-Renewal; Transcription
Abstract
"1 in 1000 Canadians over 65 will develop myelodysplastic syndrome (MDS), which causes deficiencies in mature blood cells due to malignant hematopoietic stem cells (HSCs) and may progress to secondary acute myeloid leukemia. The only cure for MDS are bone marrow (BM) transplants which are dangerous for elderly patients, indicating a need for new therapeutics. Splicing factors are mutated in 60% of cases, suggesting that RNA splicing may be a key pathogenic pathway. By analyzing RNA sequencing data from healthy and MDS BM, we identified <em>MBD1</em>, a DNA binding protein that represses gene expression, as a globally mis-spliced transcript in MDS and a candidate therapeutic target. We identified exon inclusion events that add new repressive capabilities, potentially representing therapeutically relevant gain-of-function events. As most causal mis-spliced transcripts in MDS are loss-of-function isoforms, our identification of <em>MBD1</em> mis-splicing may highlight a novel mechanism through which alternative splicing can contribute to MDS. In this project, my two objectives are to determine whether increased inclusion of exon 10 or 12 promotes MDS pathology, and the associated mechanism. For my first objective, I will use lentivirally encoded dCasRx to perform exon knockdown and overexpression in the MDSL cell line and primary MDS samples to run clonal competitive assays to define whether exon 10 or 12 promote MDS growth. For my second objective, I will use integrative CHIP-seq and RNA-seq on primary MDS samples and healthy human HSCs to determine altered promoter binding and gene repression due to <em>MBD1</em> mis-splicing. By studying <em>MBD1</em> mis-splicing in MDS, I will uncover a new and tractable therapeutic target for MDS while uncovering new ways through which splicing can contribute to MDS."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Joshi, Pratik
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~